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A B S T R A C T
Gene therapy has become a reality, although still a fragile one. Clinical beneﬁt has been
achieved over the last 17 years in a limited number of medical conditions for which
pathophysiological studies determined that they were favorable settings. They include
inherited disorders of the immune system, leukodystrophies, possibly hemoglobinopa-
thies, hemophilia B, and retinal dystrophies. Advances in the treatment of B-cell leukemias
and lymphomas have also been achieved. Advances in vector development and possible
usage of gene editing may lead to signiﬁcant advances over the next years.
 2016 Published by Elsevier Masson SAS on behalf of Acade´mie des sciences. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
R E´ S U M E´
Bien qu’encore fragile, la the´rapie ge´nique est devenue une re´alite´. Un be´ne´ﬁce clinique a e´te´
obtenu au cours des 17 dernie`res anne´es dans un nombre limite´ de conditions me´dicales pour
lesquelles des e´tudes physiopathologiques avaient de´termine´ qu’elles e´taient favorables. Il
s’agit des troubles he´re´ditaires du syste`me immunitaire, des leucodystrophies, e´ventuel-
lement des he´moglobinopathies, d’he´mophilie B et des dystrophies re´tiniennes. Des progre`s
dans le traitement des leuce´mies a` cellules B et de certains lymphomes ont e´galement e´te´
accomplis. Les progre`s dans le de´veloppement de vecteurs et la possibilite´ d’utiliser
l’inge´nierie ge´nomique cible´e pourront conduire a` des progre`s importants au cours des
prochaines anne´es.
 2016 Publie´ par Elsevier Masson SAS au nom de Acade´mie des sciences. Cet article est
publie´ en Open Access sous licence CC BY-NC-ND (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Gene therapy has attracted many scientists and
linicians for its potential to ﬁx a disease based on genes.
his was initially viewed as a way to correct genetic
iseases, but further applications were rapidly considered
ince genes products can convey cells with characteristics
f medical interest to ﬁght cancer or protect from cell
egeneration, for example. Ease in gene manipulation,
ddition of regulatory elements and usage of viruses
ostly to drive entry into cells to target made this concept
otentially feasible as envisaged in the early 1970s [1].
Nevertheless, it was rapidly perceived, despite a
umber of unsubstantiated claims, that gene transfer
eeds to be efﬁcacious to overcome many hurdles. They
clude targeting of the appropriate cell lineage(s),
btaining a sufﬁcient but not excessive level of gene
xpression, maintaining its expression over time, avoiding
e genotoxic effects of the material if integrated into the
ells’ genome, limiting/eliminating immune reaction
gainst the vectors and/or the gene’s product. . . This
xplains, why for many years, the multiple attempts,
otably in the area of cancer, failed, leading to skepticism
bout its future. In addition, the gene therapy strategy has
 be based on an appropriate understanding of the
athophysiology of the disease to treat [2].
. Strategy and vectors
Today, available technologies made feasible both ex
ivo and in vivo gene therapy based on the persistence of
e transgene either non-integrated or integrated in the
enome. The former approach is appropriate to target post-
itotic cells, while the second is necessary to target
itotic cells (such as hematopoietic cells, for instance).
deno-associated viral vectors (AAVs) are well matched
r the ﬁrst approach. They can infect virtually all cell types
nd permit to achieve stable transgene maintenance. Such
ectors can relatively easily be engineered as non-
eplicative viruses and produced as very large batches.
conveniencies rely on the relatively limited size of
enetic material that can be delivered and on its
munogenicity. Indeed AAVs naturally infect humans
ho develop effective immune responses against its
omponents, which can lead to neutralization of efﬁcacy
y destruction of transduced cells. Some AAV strains (such
AV8 or 9) do less frequently infect humans, leaving some
pportunity for application (see below) [3].
Retroviruses offer the capacity of leading to integration
to the genome. Gamma retroviruses, then lentiviruses
ave been designed to carry the genetic material into the
ells and lead to stable integration into the genome(s)
]. HIV-based lentiviral vectors are particularly attractive
ince their provirus can integrate both in dividing (like g
etroviral vectors) but also in non-dividing in the G1 phase
f the cell cycle [5]. The major drawback of the utilization
f retroviral vectors is the semi-random character of their
tegration, which can cause genotoxicity (see below).
Gene therapy can be considered as a way to add the
opy of a gene, to modify a gene (for instance to skip a
utated exon), to inactivate a gene (for instance in the
setting of a dominant mutation with a trans negative
effect) or to correct a gene mutation based on recombinant
technology.
3. Applications
3.1. The hematopoietic system
The ﬁrst success of gene therapy were achieved around
the year 2000 in the very speciﬁc ﬁeld of treating severe
inherited T-cell immune deﬁciencies by ex vivo gene
transfer into hematopoietic stem (HS) or progenitor cells
(C). Several reasons account for that. HSCs are accessible
while the prospect of modifying HSCs should provide
lasting beneﬁt. In addition, T cells are known to be long
lived and the analysis of rare revertant cases from severe
combined immune deﬁciencies – sort of natural gene
therapy – showed that precursor T cells can expand,
providing demultiplication of gene transfer. Two diseases,
severe combined immunodeﬁciency X1 (SCID X1) and
adenosine deaminase deﬁciency (ADA), have thus been
treated with success by using g retroviral-mediated gene
transfer into hematopoietic progenitor cells [6,7]. The
efﬁcacy has now been found sustained for 17 years since
patients exhibit close to or normal T lymphocyte counts
and function, enabling them to live normally. Nearly
100 patients have now been successfully treated world-
wide [8–10]. Nevertheless, this success was tempered by
the occurrence in the SCID X1 gene therapy trials (ﬁve
cases) and in other trials of cases of leukemia [11]. The
latter originated from oncogene transactivation by the
viral enhancer from the long terminal repeat (LTR)
following proviral integration within the oncogene locus.
These unanticipated genotoxic events led to halt clinical
trials. Once the mechanism was understood, a new
generation of vectors was produced, in which the viral
LTR was deleted and instead an internal promoter was
used, the so-called self-inactivated (SIN) vectors. These SIN
vectors have now been used with success and safety with a
follow up reaching more than eight years for several
diseases including SCIDX1 [12,13].
The ﬁrst successes of gene therapy were obtained in a
favorable setting because of the selective advantage
provided to the transduced cells. Utilization of vectors
that are more potentially able to transduce HSCs, i.e.
lentiviral vectors, have now been used with success to treat
additional genetic diseases, including the Wiskott–Aldrich
syndrome, another form of primary immunodeﬁciency
[14,15] and then leukodystrophies, for which gene
addition in the monocyte cell lineage was of interest
[16,17]. The extension of indications to many more genetic
diseases of hematopoiesis is being envisaged; it includes
several primary immune deﬁciencies, but also Fanconi
anemia or genetic disorders of hemoglobin (b-thalassemia
and sickle cell disease).
The latter represents a formidable challenge, as
transgene (b-globin) expression needs to be restricted to
the erythropoietic lineage. Introduction of the regulatory
locus control region makes it feasible. First trials have been
initiated with promising preliminary results [18]. An
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A. Fischer / C. R. Biologies 339 (2016) 314–318316ernative strategy, such as promoting the expression of
tal hemoglobin by inactivating a regulatory transcription
ctor, appears as particularly elegant.
. Other applications in the ﬁeld of inherited diseases
The liver is a potentially good target for in vivo
travenous) AAV vector-based gene therapy. It has been
imarily used to treat hemophilia B factor (factor IX
ﬁciency). While the ﬁrst attempts failed because immune
sponses of pre-immunized recipients to the AAV2 virus
minated transduced hepatocytes, the recent choice to use
stead AAV8 in naı¨ve recipients led to a sustained
 4 years) persistence of FIX plasma expression, sufﬁcient
 avoid most of the clotting factor replacement injections
9,20]. No side effects were observed. Another useful
plication of the same technology consists of an intraocular
bretinal) injection of AAV vectors containing a normal
copy of genes mutated in various forms of inherited retinal
dystrophies. These attempts were found safe, did not
generate immune responses, and led to some improvement
in sight that can be sustained at least for some years,
provided that patients are not treated too late when retinal
cells to be targeted are lost [21–23]. Many more projects
based on AAV or lentiviral vectors are being tested to treat a
variety of inherited disorders affecting brain (mucopolysac-
charidosis), muscle (myopathies), or liver (several metabolic
diseases) [24]. They have not yet reached the stage where
clinical beneﬁts have been demonstrated, in part because
targeting of diseased cells (brain and muscle, but also lungs)
remains a serious challenge.
4. Gene therapy of cancer
After years of failures, ﬁrst convincing results were
achieved over the last ﬁve years with a strategy consistingFig. 1. Two strategies for gene therapy: gene addition and gene editing.
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apable of recognizing a membrane protein at the surface
f cancer cells and activating these T cells to kill the target
ells. Such chimeric antigen receptors (CAR) have been
ngineered based on a variable domain of immunoglobulin
ecognition unit) coupled with potent activation trans-
ucing domains. This technology has been successfully
pplied to the treatment of B-cell leukemias and lympho-
as by targeting an intrinsic membrane B-cell molecule
D19). Lentiviral vectors were designed to ex vivo
ansduce the patients’ T cells. Several clinical trials have
emonstrated that this approach can induce remission in
atients with refractory disease [25,26]. The loss of B cells
an be compensated by immunoglobulin supplementa-
on. Although some adverse events can be generated by
e potency of the inﬂammation reaction, this strategy is
ufﬁciently promising to enable several pharmaceutical
ompanies to investigate now its development, with the
dditional aim to design CAR able to recognize molecules
n solid tumors too.
. Further prospects
A number of challenges remain ahead of the develop-
ent of gene therapy for it to become some form of standard
eatment. Large-scale manufacturing of vectors remains an
sue, although advances have been readily achieved. New
chnologies, particularly based on targeted gene editing
ig. 1) mediated by engineered nucleases, appear particu-
rly appealing. The successive generation of such modiﬁed
nzymes: Zn ﬁnger nucleases, Talen and now RNA guided
as 9 make it today feasible to very speciﬁcally target
enome modiﬁcations [27]. A ﬁrst usage will be gene
activation by letting targeted DNA breaks in a given gene
e repaired with errors by the non-homologous DNA end
ining (NHEJ). This has entered clinical testing by
isrupting with adapted Zn ﬁnger nucleases both alleles
f the HIV CCR5 receptor encoding genes in T cells to protect
em from infection [28]. The safety and the long-term
ersistence of such cells have been demonstrated, although
 will be needed to signiﬁcantly increase the number of
rgeted cells for it to be effective. The very same strategy is
eing experimentally tested to inactivate the expression of a
utated exon – for instance – in the dystrophin gene
ssociated with myopathies [29] or to extinguish the
xpression of molecules involved in unwanted immune
esponses, such as HLA antigens, to avoid the rejection of
otentially ‘‘universal’’ corrected cells as envisaged with
ngineered anti-cancer T cells.
The same technology may be used to initiate homolo-
ous recombination at a desired locus to replace a
utation by a wild-type sequence. Proofs of principles
f success have been achieved in cell lines [30] and animal
odels of inherited diseases, such as SCID X1 tyrosinemia
1] or urea cycle deﬁciency [32]. Still, the frequency of cell
diting and the issue of potential off targets (i.e. non-locus-
peciﬁc recombination) need to be addressed. Some have
dvocated that one day this technology could be used to
epair germ line mutation in embryos. Although techni-
ally it may become feasible, the raised ethical questions,
avoid the birth of affected children, represent a barrier that
is likely not to be trespassed.
6. Conclusion
Combination of gene therapy with stem cell technology
may widen its scope once the latter will be mastered up to
the point of medical application of gene therapy to
medicine. In any case, it should remain clear that gene
therapy will never be more than one additional strategy in
the armamentarium of therapeutics, but this will be a
signiﬁcant achievement!
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